Billing and Coding: MolDX: Minimal Residual Disease Testing for Solid Tumor Cancers (A58454) - R7 - Effective July 11, 2024

Date Posted: July 11, 2024

This Local Coverage Article (LCA) has been revised under contractor numbers: 02102 (AK), 02202 (ID), 02302 (OR), 02402 (WA), 03102 (AZ), 03202 (MT), 03302 (ND), 03402 (SD), 03502 (UT), and 03602 (WY).

Effective Date: July 11, 2024

Summary of Changes:

Under Article Text revised Table 1 row 3 to add "RaDaR Whole Exome + Plasma Series Bundle for Molecular Residual Disease (NeoGenomics Laboratories, Inc)". Under subheading Additional Test-specific Indications, Limitations and Instructions revised first sentence to add "HPV-negative head and neck squamous cell carcinoma (RaDaR)". Formatting was corrected throughout the article. This revision is due to new covered test that has successfully completed a TA and is effective for 3/20/2024.

Under CPT/HCPCS Codes Group 3: Codes added 81479. This is effective 7/11/2024.

Visit the Noridian Active LCDs webpage to view the document or access it via the CMS MCD.

Last Updated $dateUtil.getDate( $modifieddate , "MMM dd , yyyy" , $locale , $tzone )